title: Developing a pediatric outpatient transplantation program. The Children's Memorial Hospital experience.
abstract: We describe the development of a pediatric outpatient transplant program and our initial experience with autologous and allogeneic transplants performed partially or completely in the outpatient setting. Forty-eight autologous and seven allogeneic transplants have been performed in our institution in the outpatient setting between June 1994 and July 2000. The ablation used for the autologous outpatient transplants was VP-16 1000 mg/m2/ day as a continuous infusion for 2 days and Carboplatinum 667mg/m2/day for 2 days. The autologous inpatient transplants received Thio-tepa 300-mg/ m2per day x 3 days and cyclophosphamide 60 mg/kg/day for 4 days. For those patients who received an immune-ablative allogeneic outpatient transplant, the regimen consisted of Fludarabine 30 mg/m2/day for 6 days, followed by busulfan for children less than five years of age 1 mg/kg/dose x 8 doses and for those five years and older 0.8 mg/kg/dose x 8 doses, followed by ATG 40mg/kg/day x 4 days. Engraftment was complete in all transplants achieving an ANC >500 for the outpatient transplant in 15 days (10-35) vs. the inpatient in 15 days (14-58). This was not statistically significant. They achieved un-sustained platelets >20.0 by day 19 (14-58) for the outpatients and day 32 10-64) for the inpatient. The allogeneic immune ablative transplants were considered engrafted when their VNTRs were greater that 30% which was achieved at a median of 13 days (10-27). The economic data showed a statistically significant decrease in charges and direct costs between the outpatient (median charges $30 775, direct costs $8 389) and the inpatient (median charges $99 838, direct costs $42 757) transplants (p0.001). There was no difference in morbidity and mortality between the two groups but the use of empiric amphotericin B was markedly decreased in the outpatient transplants. In conclusion it is feasible and less costly to perform autologous hematopoietic stem cell transplants in the outpatient setting with no increase in morbidity and mortality. For the allogeneic transplants there is not yet enough data to establish a similar conclusion.
authors.affiliation: Children's Memorial Hospital, Stem Cell Transplant Program at Children's Memorial Hospital, 2300 Children's Plaza, Chicago IL 60614, USA.
authors.forename: L
authors.initials: L
authors.lastname: Gonzalez-Ryan
authors.forename: P R
authors.initials: PR
authors.lastname: Haut
authors.forename: K
authors.initials: K
authors.lastname: Coyne
authors.forename: K V
authors.initials: KV
authors.lastname: Syckle
authors.forename: R
authors.initials: R
authors.lastname: Duerst
authors.forename: D
authors.initials: D
authors.lastname: Haro
authors.forename: M
authors.initials: M
authors.lastname: Kletzel
mesh_terms: D000556:Ambulatory Surgical Procedures / Q000191:economics / Q000379:methods*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics / Q000379:methods*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007223:Infant; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous
chemical_list: D007166:Immunosuppressive Agents